BioCardia, Inc. (BCDA) Financials

BCDA

FY2025 annual

Revenue $0 -100.0% YoY

Net Income -$8.2M -3.5% YoY

Free Cash Flow -$7.4M +5.7% YoY

Operating Cash Flow -$7.4M +5.7% YoY

Market Cap $16.5M as of Oct 7, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 6.1x on $2.7M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 12, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BCDA SEC filings page.

BioCardia, Inc. (BCDA) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BCDA FY2025 2026-10-03

BioCardia's development-stage business had FY2024 revenue of $58K against operating cash use of $7.9M.

Cash conversion was straightforward in FY2024: operating cash use of $7.9M nearly matched the $7.9M net loss, so losses translated into cash needs rather than mainly reflecting non-cash charges. Capital spending was only $6K, pointing to a model funded primarily by operating expenses and R&D rather than equipment investment.

External financing supplied $7.6M in FY2025 against operating cash use of $7.4M, indicating that reported cash resources were being replenished through financing rather than sales. The reported liquidity comparison was 4 months of annual operating outflow, making financing activity central to the balance-sheet picture.

Equity moved from negative -$1.6M in FY2023 to positive $895K in FY2025, indicating a reversal from balance-sheet deficit. Even so, debt-to-equity was 2.8x and the current ratio was 1.1x, leaving a thin capital cushion relative to obligations.

Financial Health Signals

Financial health score not available

BioCardia, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-73.02

BioCardia, Inc. scores -73.02, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($16.5M) relative to total liabilities ($2.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

BioCardia, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

BioCardia, Inc. reported a net loss of $8.2M while operations used $7.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$1.6M

YoY+20.8%

QoQ+28.4%

BioCardia, Inc.'s EBITDA was -$1.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 20.8% from the same quarter a year earlier. Against the prior quarter it is up 28.4%.

Net Income

-$1.6M

YoY+21.3%

QoQ+28.6%

BioCardia, Inc. reported -$1.6M in net income in Q2 2026. This represents an increase of 21.3% from the same quarter a year earlier. Against the prior quarter it is up 28.6%.

Revenue

Not reported for Q2 2026.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$1.7M

YoY-5.2%

QoQ-4.4%

BioCardia, Inc. recorded an outflow of $1.7M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 5.2% from the same quarter a year earlier. Against the prior quarter it is down 4.4%.

Cash & Debt

$4.1M

YoY+320.1%

QoQ+332.9%

5Y CAGR-26.0%

10Y CAGR+9.3%

BioCardia, Inc. held $4.1M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

15M

QoQ+33.1%

5Y CAGR-2.1%

10Y CAGR-23.8%

BioCardia, Inc. had 15M shares outstanding in Q2 2026. Against the prior quarter it is up 33.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-59.7%

BioCardia, Inc.'s ROE was -59.7% in Q2 2026, measuring profit generated per dollar of shareholder equity.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$893K

YoY-34.7%

QoQ-27.7%

BioCardia, Inc. invested $893K in research and development in Q2 2026. This represents a decrease of 34.7% from the same quarter a year earlier. Against the prior quarter it is down 27.7%.

Capital Expenditures

YoY-100.0%

QoQ-100.0%

BioCardia, Inc. reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q2 2026.

BCDA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BCDA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	$0-100.0%	$58K-87.8%	$477K-64.7%	$1.4M+33.2%	$1.0M+600.0%	$145K-79.6%	$710K+13.6%	$625K+30.5%	$479K-16.8%	$576K-36.3%	$904K	N/A	N/A	$62K+416.7%	$12K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$4K-98.9%	$358K-30.8%	$517K-25.1%	$690K-7.5%	$746K-29.7%	$1.1M	N/A	N/A	$0	$0
Gross Profit	N/A	N/A	N/A	N/A	N/A	$1.0M+619.9%	$141K-59.9%	$352K+225.9%	$108K+151.2%	-$211K-24.1%	-$170K-8.3%	-$157K	N/A	N/A	$62K+416.7%	$12K
R&D Expenses	N/A	$5.0M+13.1%	$4.4M-43.2%	$7.7M-12.5%	$8.8M+3.2%	$8.6M-12.8%	$9.8M+14.6%	$8.6M+1.3%	$8.5M+45.8%	$5.8M+74.1%	$3.3M+119.4%	$1.5M	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	$3.3M-9.7%	$3.7M-16.5%	$4.4M-0.5%	$4.4M-13.1%	$5.1M-13.2%	$5.9M-2.4%	$6.0M+4.3%	$5.8M-10.0%	$6.4M+55.7%	$4.1M+10.0%	$3.7M+1805.1%	$196K-24.3%	$259K-35.4%	$401K-36.3%	$630K
Operating Income	N/A	-$8.3M-3.5%	-$8.0M+31.3%	-$11.6M+2.2%	-$11.9M+5.8%	-$12.6M+18.7%	-$15.5M-9.3%	-$14.2M-0.8%	-$14.1M-13.7%	-$12.4M-63.1%	-$7.6M-40.7%	-$5.4M-2441.6%	$231K+2466.7%	$9K+102.7%	-$339K+45.1%	-$618K
EBITDA	N/A	-$8.3M-4.0%	-$7.9M+31.4%	-$11.6M+2.2%	-$11.8M+6.0%	-$12.6M+18.7%	-$15.5M-9.6%	-$14.1M-0.6%	-$14.0M-13.7%	-$12.3M-62.9%	-$7.6M-41.2%	-$5.4M	N/A	N/A	N/A	-$618K
Interest Expense	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$3K-97.3%	$112K	N/A	$0-100.0%	$1.7M+25.3%	$1.4M	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	N/A	-$8.2M-3.5%	-$7.9M+31.3%	-$11.6M+2.8%	-$11.9M+5.7%	-$12.6M+15.9%	-$15.0M-2.0%	-$14.7M-5.2%	-$14.0M-13.6%	-$12.3M-19.4%	-$10.3M-53.9%	-$6.7M-2962.0%	$234K+1131.6%	$19K-93.8%	$305K-96.8%	$9.7M
EPS (Basic)	N/A	-$1.23+57.6%	-$2.90+64.6%	-$8.19-1122.4%	-$0.67+10.7%	-$0.75	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	230M0.0%	230M0.0%	230M0.0%	230M0.0%	230M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q/A	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	$0	$0-100.0%	$0-100.0%	N/A	$0-100.0%
R&D Expenses	$893K-34.7%	$1.2M-19.3%	N/A	$936K+0.5%	$1.4M+71.0%	$1.5M+23.3%	N/A	$931K-50.3%
SG&A Expenses	$730K+6.9%	$1.0M-13.8%	N/A	$552K-33.1%	$683K-19.8%	$1.2M+9.8%	N/A	$825K-23.8%
Operating Income	-$1.6M+20.9%	-$2.3M+16.9%	N/A	-$1.5M+15.3%	-$2.1M-24.4%	-$2.7M-19.8%	N/A	-$1.8M+32.4%
EBITDA	-$1.6M+20.8%	-$2.3M+16.6%	N/A	-$1.5M+14.7%	-$2.0M-25.4%	-$2.7M-20.3%	N/A	-$1.7M+32.5%
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$1.6M+21.3%	-$2.3M+16.7%	N/A	-$1.5M+14.6%	-$2.0M-24.5%	-$2.7M-19.6%	N/A	-$1.7M+32.5%
EPS (Basic)	-$0.13+67.5%	-$0.21+64.4%	-$0.06+76.0%	-$0.24+60.7%	-$0.40+54.5%	-$0.59+56.3%	-$0.25+81.1%	-$0.61+65.9%
EPS (Diluted)	N/A	-$0.21	N/A	N/A	-$0.40	-$0.59	N/A	N/A
Diluted Shares (Avg)	N/A	11M	N/A	N/A	5M	5M	N/A	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

BCDA Balance Sheet

BCDA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$3.4M-8.4%	$3.7M+24.7%	$3.0M-69.5%	$9.8M-37.7%	$15.7M-32.9%	$23.4M+205.1%	$7.7M+19.7%	$6.4M-52.6%	$13.5M-38.7%	$22.1M+354.2%	$4.9M-65.0%	$13.9M+2.4%	$13.5M+1.8%	$13.3M-3.2%	$13.7M
Current Assets	$2.7M+4.2%	$2.6M+79.5%	$1.5M-81.4%	$7.9M-41.7%	$13.5M-40.5%	$22.7M+255.3%	$6.4M+2.6%	$6.2M-53.3%	$13.3M-39.2%	$21.9M+369.4%	$4.7M	N/A	N/A	$13.3M-3.2%	$13.7M
Cash & Equivalents	$2.5M+5.3%	$2.4M+115.0%	$1.1M-85.0%	$7.4M-42.8%	$12.9M-39.9%	$21.4M+283.3%	$5.6M+4.2%	$5.4M-57.8%	$12.7M-40.6%	$21.4M+500.3%	$3.6M+11.7%	$3.2M-76.1%	$13.3M+0.2%	$13.3M+4.7%	$12.7M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	$4K-97.2%	$141K-26.2%	$191K+41.5%	$135K-82.2%	$759K	N/A	N/A	N/A	N/A
Accounts Receivable	$20K	$0-100.0%	$63K-68.7%	$201K+36.7%	$147K-36.6%	$232K+57.8%	$147K-46.4%	$274K+188.4%	$95K+28.4%	$74K-30.8%	$107K	N/A	N/A	$0-100.0%	$67K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.5M-12.8%	$2.9M-37.1%	$4.6M-6.3%	$4.9M-8.3%	$5.3M+25.8%	$4.2M-20.0%	$5.3M+102.2%	$2.6M+8.8%	$2.4M+60.9%	$1.5M-81.9%	$8.3M-85.4%	$57.0M+5699200.0%	$1K-91.7%	$12K-98.4%	$756K
Current Liabilities	$2.4M+4.8%	$2.3M-35.7%	$3.6M+0.6%	$3.6M-3.4%	$3.7M-12.6%	$4.2M+6.1%	$4.0M+57.1%	$2.5M+9.3%	$2.3M+61.5%	$1.4M-82.6%	$8.3M	N/A	N/A	N/A	N/A
Non-Current Liabilities	$86K-84.8%	$566K-42.4%	$982K-25.4%	$1.3M-19.3%	$1.6M	$0-100.0%	$1.3M+1594.8%	$77K-4.9%	$81K+44.6%	$56K	$0	N/A	N/A	N/A	N/A
Total Equity	$895K+6.9%	$837K+152.2%	-$1.6M-132.8%	$4.9M-52.8%	$10.4M-45.9%	$19.2M+709.1%	$2.4M-37.5%	$3.8M-65.9%	$11.1M-45.9%	$20.6M+698.0%	-$3.4M+92.0%	-$43.1M-423.9%	$13.3M+0.2%	$13.3M+2.4%	$13.0M
Retained Earnings	-$168.3M-5.1%	-$160.1M-5.2%	-$152.2M-8.2%	-$140.6M-9.3%	-$128.7M-10.9%	-$116.1M-14.8%	-$101.1M-17.0%	-$86.4M-19.2%	-$72.5M-20.5%	-$60.1M-20.7%	-$49.8M-310.7%	-$12.1M+2.6%	-$12.5M+2.0%	-$12.7M+2.3%	-$13.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q/A	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$4.8M+127.6%	$1.7M-21.0%	$3.4M-8.4%	$6.1M-1.9%	$2.1M-27.7%	$2.2M-19.1%	$3.7M+24.7%	$6.3M+67.3%
Current Assets	$4.3M+258.5%	$1.1M-2.8%	$2.7M+4.2%	$5.4M+6.1%	$1.2M-23.8%	$1.2M-6.8%	$2.6M+79.5%	$5.1M+138.9%
Cash & Equivalents	$4.1M+320.1%	$951K+0.2%	$2.5M+5.3%	$5.3M+7.2%	$980K-31.0%	$949K0.0%	$2.4M+115.0%	$4.9M+168.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$30K+200.0%	$20K	$20K	N/A	$10K0.0%	N/A	$0-100.0%	$10K-90.4%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.1M-48.3%	$2.8M-24.6%	$2.5M-12.8%	$3.5M+0.2%	$4.0M-18.1%	$3.7M-25.6%	$2.9M-37.1%	$3.5M-20.3%
Current Liabilities	$2.1M-43.6%	$2.8M-14.1%	$2.4M+4.8%	$3.3M+16.5%	$3.6M-10.5%	$3.2M-20.6%	$2.3M-35.7%	$2.8M-14.7%
Non-Current Liabilities	$0-100.0%	$0-100.0%	$86K-84.8%	$211K-68.7%	$333K-57.3%	$452K-48.8%	$566K-42.4%	$674K-37.4%
Total Equity	$2.7M+243.2%	-$1.1M+29.9%	$895K+6.9%	$2.6M-4.6%	-$1.9M+3.8%	-$1.5M+33.2%	$837K+152.2%	$2.8M+517.1%
Retained Earnings	-$172.2M-4.5%	-$170.6M-4.8%	-$168.3M-5.1%	-$166.4M-5.4%	-$164.9M-5.6%	-$162.8M-5.4%	-$160.1M-5.2%	-$157.8M-5.1%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

BCDA Cash Flow Statement

BCDA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$7.6M	-$7.4M+5.7%	-$7.9M+20.9%	-$10.0M+5.6%	-$10.6M-1.9%	-$10.4M+16.1%	-$12.4M-30.8%	-$9.4M+14.7%	-$11.1M-27.7%	-$8.7M-57.0%	-$5.5M+21.4%	-$7.0M-3381.8%	$214K+692.6%	$27K+108.7%	-$310K+90.0%	-$3.1M
Depreciation & Amortization	N/A	$24K-64.2%	$67K-20.2%	$84K+2.4%	$82K+36.7%	$60K-11.8%	$68K-38.7%	$111K+26.1%	$88K+12.8%	$78K+100.0%	$39K-17.0%	$47K	N/A	N/A	N/A	$0
Stock-Based Compensation	N/A	$430K-42.0%	$741K-28.1%	$1.0M-12.9%	$1.2M-28.8%	$1.7M-43.7%	$3.0M+8.4%	$2.7M-1.9%	$2.8M+2.5%	$2.7M+187.4%	$942K+232.9%	$283K	$0-100.0%	$2K-66.7%	$6K-83.8%	$37K
Capital Expenditures	$9K	$7K+16.7%	$6K-50.0%	$12K-82.9%	$70K-39.7%	$116K+262.5%	$32K-78.1%	$146K+121.2%	$66K-51.5%	$136K	N/A	$125K	N/A	N/A	$0-100.0%	$137K
Free Cash Flow	-$7.6M	-$7.4M+5.7%	-$7.9M+21.0%	-$10.0M+6.1%	-$10.6M-1.4%	-$10.5M+15.4%	-$12.4M-29.2%	-$9.6M+13.9%	-$11.1M-26.4%	-$8.8M	N/A	-$7.1M	N/A	N/A	-$310K+90.4%	-$3.2M
Investing Cash Flow	-$9K	-$7K-16.7%	-$6K+50.0%	-$12K+82.9%	-$70K+39.7%	-$116K-262.5%	-$32K+78.1%	-$146K-121.2%	-$66K+51.5%	-$136K-100.7%	$18.9M+15236.8%	-$125K	N/A	$0-100.0%	$900K-94.4%	$16.1M
Financing Cash Flow	$10.7M	$7.6M-17.4%	$9.2M+145.8%	$3.7M-27.3%	$5.1M+163.1%	$1.9M-93.1%	$28.2M+187.3%	$9.8M+158.1%	$3.8M+2541.7%	$144K-96.7%	$4.4M-41.6%	$7.5M	N/A	N/A	$0+100.0%	-$500K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q/A	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.7M-5.2%	-$1.7M-2.5%	-$2.5M-2.6%	-$1.7M+36.0%	-$1.6M-25.7%	-$1.6M-5.8%	-$2.4M-31.4%	-$2.6M-8.3%
Depreciation & Amortization	$3K-40.0%	$3K-75.0%	$3K-80.0%	$4K-75.0%	$5K-70.6%	$12K-36.8%	$15K-25.0%	$16K-23.8%
Stock-Based Compensation	$109K+11.2%	$113K-33.5%	N/A	$77K-56.5%	$98K-46.7%	$170K-16.7%	N/A	$177K-29.5%
Capital Expenditures	$0-100.0%	$3K	$6K+500.0%	$0-100.0%	$1K-66.7%	$0	$1K	$2K
Free Cash Flow	-$1.7M-5.2%	-$1.7M-2.7%	-$2.5M-2.8%	-$1.7M+36.0%	-$1.6M-25.5%	-$1.6M-5.8%	-$2.4M-31.5%	-$2.6M-8.3%
Investing Cash Flow	$0+100.0%	-$3K	-$6K-500.0%	$0+100.0%	-$1K+66.7%	$0	-$1K	-$2K
Financing Cash Flow	$4.9M+191.6%	$117K-40.3%	-$288K-130.4%	$6.0M-2.3%	$1.7M-5.9%	$196K-85.8%	-$125K-111.2%	$6.1M+10655.2%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BCDA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BCDA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	100.0%+2.8pp	97.2%+47.7pp	49.6%+32.3pp	17.3%+61.3pp	-44.0%-14.5pp	-29.5%-12.1pp	-17.4%	N/A	N/A	100.0%0.0pp	100.0%
Operating Margin	N/A	-13794.8%	-2441.1%	-880.3%	-1244.3%	-10709.7%	-2001.8%	-2256.3%	-2589.8%	-1320.8%	-598.3%	N/A	N/A	-546.8%	-5150.0%
Net Margin	N/A	-13700.0%	-2425.8%	-880.7%	-1243.7%	-10347.6%	-2071.7%	-2237.9%	-2569.5%	-1789.9%	-740.8%	N/A	N/A	491.9%	80516.7%
Return on Equity	-919.3%+30.0pp	-949.3%	N/A	-243.4%-121.7pp	-121.7%-43.4pp	-78.2%+542.4pp	-620.6%-251.8pp	-368.9%-258.2pp	-110.6%-60.5pp	-50.1%	N/A	N/A	0.1%-2.2pp	2.3%-72.2pp	74.5%
Return on Assets	-241.1%-27.7pp	-213.4%+174.0pp	-387.4%-265.8pp	-121.6%-41.3pp	-80.3%-16.3pp	-64.0%+127.5pp	-191.6%+26.4pp	-218.0%-127.1pp	-90.9%-44.2pp	-46.7%+91.0pp	-137.7%-139.4pp	1.7%+1.5pp	0.1%-2.2pp	2.3%-68.1pp	70.3%
Current Ratio	1.120.0x	1.13+0.7x	0.40-1.8x	2.19-1.4x	3.63-1.7x	5.33+3.7x	1.59-0.8x	2.44-3.3x	5.71-9.5x	15.18+14.6x	0.56	N/A	N/A	N/A	N/A
Debt-to-Equity	2.81-0.6x	3.45	N/A	1.00+0.5x	0.52+0.3x	0.22-2.0x	2.24+1.5x	0.69+0.5x	0.22+0.1x	0.07	N/A	N/A	0.000.0x	0.00-0.1x	0.06
Asset Turnover	0.000.0x	0.02-0.1x	0.160.0x	0.14+0.1x	0.06+0.1x	0.01-0.1x	0.090.0x	0.10+0.1x	0.040.0x	0.03-0.2x	0.19	N/A	N/A	0.000.0x	0.00
FCF Margin	N/A	-13606.9%	-2093.5%	-786.3%	-1032.7%	-8544.1%	-1350.8%	-1781.6%	-1838.6%	N/A	-790.7%	N/A	N/A	-500.0%	-26866.7%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q/A	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-59.7%	N/A	N/A	-56.5%+6.6pp	N/A	N/A	N/A	-63.1%
Return on Assets	-33.9%+64.2pp	-131.9%-6.7pp	N/A	-24.1%+3.6pp	-98.1%-41.1pp	-125.2%-40.6pp	N/A	-27.7%+41.0pp
Current Ratio	2.09+1.8x	0.410.0x	1.120.0x	1.62-0.2x	0.33-0.1x	0.36+0.1x	1.13+0.7x	1.78+1.1x
Debt-to-Equity	0.76	N/A	2.81-0.6x	1.34+0.1x	N/A	N/A	3.45	1.28
Asset Turnover	N/A	N/A	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.00-0.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
BioCardia, Inc. BCDA	FY2025	$0	-$8.2M	N/A	$16.5M	—
Adaptimmune Therapeutics plc American ADAP	FY2024	$178.0M	-$70.8M	-39.8%	$14.6M	46/100
Phio Pharmaceuticals Corp. PHIO	FY2025	N/A	-$8.7M	N/A	$11.5M	—
Briacell Therapeutics Corp. BCTX	FY2025	N/A	-$26.3M	N/A	$35.0M	—
Immuron Limited IMRN	FY2023	N/A	N/A	N/A	$8.7M	—

Where BioCardia, Inc. Ranks

Frequently Asked Questions

What is BioCardia, Inc.'s annual revenue?

BioCardia, Inc. (BCDA) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BioCardia, Inc.'s revenue growing?

BioCardia, Inc. (BCDA) revenue declined by 100.0% year-over-year, from $58K to $0 in fiscal year 2025.

Is BioCardia, Inc. profitable?

No, BioCardia, Inc. (BCDA) reported a net income of -$8.2M in fiscal year 2025.

What is BioCardia, Inc.'s EBITDA?

BioCardia, Inc. (BCDA) had EBITDA of -$8.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is BioCardia, Inc.'s return on equity (ROE)?

BioCardia, Inc. (BCDA) has a return on equity of -919.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is BioCardia, Inc.'s free cash flow?

BioCardia, Inc. (BCDA) recorded an outflow of $7.4M in free cash flow during fiscal year 2025. This represents a 5.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is BioCardia, Inc.'s operating cash flow?

BioCardia, Inc. (BCDA) recorded an outflow of $7.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are BioCardia, Inc.'s total assets?

BioCardia, Inc. (BCDA) had $3.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are BioCardia, Inc.'s capital expenditures?

BioCardia, Inc. (BCDA) invested $7K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does BioCardia, Inc. spend on research and development?

BioCardia, Inc. (BCDA) invested $5.0M in research and development during fiscal year 2025.

How many shares does BioCardia, Inc. have outstanding?

BioCardia, Inc. (BCDA) had 11M shares outstanding as of fiscal year 2025.

What is BioCardia, Inc.'s current ratio?

BioCardia, Inc. (BCDA) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.

What is BioCardia, Inc.'s debt-to-equity ratio?

BioCardia, Inc. (BCDA) had a debt-to-equity ratio of 2.81 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BioCardia, Inc.'s return on assets (ROA)?

BioCardia, Inc. (BCDA) had a return on assets of -241.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BioCardia, Inc.'s P/E ratio?

BioCardia, Inc. (BCDA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $16.5M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is BioCardia, Inc.'s price-to-sales ratio?

BioCardia, Inc. (BCDA) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $16.5M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does BioCardia, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, BioCardia, Inc. (BCDA) held $2.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.4M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is BioCardia, Inc.'s Altman Z-Score?

BioCardia, Inc. (BCDA) has an Altman Z-Score of -73.02, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is BioCardia, Inc.'s Piotroski F-Score?

BioCardia, Inc. (BCDA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BioCardia, Inc.'s earnings high quality?

BioCardia, Inc. (BCDA) reported a net loss of $8.2M while operations used $7.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.